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Abstract
Background: Photodynamic therapy with a photosensitizer such as protoporphyrin-IX, a light sensitive metabolite
of heme synthesis, is a highly selective treatment for various carcinomas. In previous studies, we found a significant
down regulation of the relevant enzyme ferrochelatase in gastrointestinal carcinomas leading to an accumulation of
protoporphyrin-IX within the tumor cells. Recent studies showed that a novel anti-cancer drug, Alectinib, an orally
available, highly selective, potent second-generation inhibitor of anaplastic lymphoma tyrosinkinase binds to
ferrochelatase. Therefore, we were interested to see whether Alectinib treatment might lead to an accumulation of
protoporphyrin IX.
Methods: Tumor cells of different origin were cultured, treated with LED-light and Alectinib. Results were gained
by flow cytometry, immunohistochemistry and western blotting. Apoptosis was determined by flow cytometric
analysis of Annexin V-FITC stained cells. In addition, cells were counterstained with propidium iodide to distinguish
early apoptotic cells and late apoptotic/necrotic cells.
Results: Here, we report that photodynamic treatment of tumor cell lines of different origin in combination with
Alectinib increased protoporphyrin-IX specific fluorescence and concomitantly cell death.
Conclusions: The usage of Alectinib could be another step for enhancing the effectiveness of photodynamic
therapy. Further experiments will show whether photodynamic therapy in combination with Alectinib could be a
new strategy for the treatment of e.g. peritoneal disseminated carcinomas.
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Background
Photodynamic therapy (PDT) is a promising alternative
approach for improving cancer treatment. This approach
has several advantages such as noninvasive treatment,
repeatability without side effects, little or no scar after
healing and short treatment times. However, treatment
efficacy depends on accurate light delivery to the tumor
and sufficient tissue oxygenation. Crucial for
photodynamic therapy is the choice of a photosensitizer
such as protoporphyrin IX (PpIX), a light sensitive me-
tabolite of heme synthesis. After treatment with light,
PpIX is able to transfer that energy to molecular oxygen,
leading to generation of reactive oxygen species (ROS)
responsible for cellular oxidation and subsequent nec-
rotic and/or apoptotic cell death of tumor cells [1]. PpIX
is under extensive study as a photosensitizer for tumor
detection and photodynamic therapy [2]. On the one
hand, generation of PpIX depends on a sufficient intra-
cellular delivery of the precursor substance 5-
aminolevulinic acid (5-ALA). On the other hand,
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generation of PpIX can be increased by down-regulation
of the activity of the ferrochelatase FECH (EC 4.99.1.1),
since PpIX is converted into heme by insertion of iron
by FECH localized within the inner mitochondrial
membrane.
In previous studies, we were able to demonstrate a sig-
nificant down regulation of FECH in gastrointestinal car-
cinomas leading to the accumulation of PpIX within the
tumor cells [3]. Later, we introduced the use of a
siRNA-based probe that is capable of amplifying the spe-
cific endogenous fluorescence emission of PpIX within
cancerous tissue by inhibition of FECH expression [4].
By measuring the thermal stability of proteins ligand
binding in living cells, FECH was identified as a target of
several kinase inhibitors in recent studies [5, 6]. One of
them, Alectinib (CH5424802), is an orally available,
highly selective, potent second-generation inhibitor of
anaplastic lymphoma tyrosinkinase (ALK). These results
suggest that Alectinib is able to block the activity of
FECH. Alectinib demonstrated a favorable safety profile
and clinically meaningful response in patients with ALK-
positive metastatic NSCLC and was granted accelerated
approval by the United States Food and Drug Adminis-
tration (FDA) on December 11, 2015 [7]. Alectinib has
shown strong efficacy in the treatment of ALK-positive
non-small-cell lung cancer [8].
The aim of this study was to find out whether pre-
treatment of tumor cells with Alectinib leads to an en-
hanced concentration of PpIX due to inhibition of
FECH and how this affects the induction of cell death.
We focused on induction of PpIX in the breast cancer
cell line MDA-MB-231. First, we tried to determine
quantitatively the effect of addition of 5-ALA (section II)
and light treatment (section III) on PpIX accumulation
and cell death (section IV). Then we used this data for
assessment of the effect of Alectinib on PpIX accumula-
tion in cancer cell lines of different origin. Here, we re-
port that treatment of tumor cells with Alectinib
increased PpIX-fluorescence and concomitantly cell
death of tumor cells after photodynamic treatment.
Thus, the usage of Alectinib could be another step for




BSA, 5-aminolevulinic acid (ALA), DMSO, and 4′,6-Dia-
midino-2-phenylindole dihydrochloride hydrate (DAPI)
were purchased from Sigma-Aldrich (Munich,
Germany); RPMI cell culture medium, Dulbecco’s Modi-
fied Eagle’s Medium, fetal calf serum, phosphate buff-
ered saline, antibiotics, Trypsin/EDTA and L-Glutamine
from GIBCO (Eggenstein, Germany), and Accutase form
BIOZOL (Eching, Germany). Alectinib and Crizotinib
were bought from Absource Diagnostics GmbH (Mun-
ich, Germany) solved in DMSO (1mM stock solution)
and stored at − 20 °C. Annexin V-FITC Apoptosis Detec-
tion KIT was obtained from BD-Biosciences (Heidelberg,
Germany). Fluorescent mounting antifading reagent was
obtained from (DAKO, CA, USA).
LED light source
A special light device has been constructed to allow illu-
mination with light of defined spectral composition and
calibrated intensity. A Light Emitting Diode (LED)
UV5TZ-405-30 (Bivar Inc., Irvine, CA) was placed into
the center of a 30 mm concave reflector. The LED emits
light at a center wavelength of 405 nm. The half-width
Δλ of the spectral profile is 35 nm. Illumination intensity
(power per area) was measured with a “Solo 2” Laser
Power and Energy Meter (Gentec-EO, Quebec, Canada)
in the center of the illuminated area and at different dis-
tances (Supplemental Fig. 4). A desired intensity was
achieved by adjustment of the supply current. Within
experiments, the LED lamp was directly positioned 25
mm above the tissue culture 6 well plate for cell incuba-
tion (Sarstedt AG & Co., Nümbrecht, Germany), with an
intensity of 4 mW/cm2.
Cell culture
Human breast cancer cell lines MDA-MB-231 (ACC
732, Deutsche Sammlung für Mikroorganismen und
Zellkulturen DSMZ, Braunschweig, Germany) and colo-
rectal carcinoma cells SW480 (CCL-228, ATCC, Manas-
sas, VA, USA) were maintained in RPMI (PAA
Laboratories, Pasching, Austria) supplemented with 10%
FCS (PAA Laboratories), 2 mM Glutamine. Gastric car-
cinoma cells MKN28 (JCRB0253, JCRB Cell Bank,
Tokyo, Japan), and NSCLC cancer cell lines NCI-H460
(HTB-177, ATCC) and NCI-H1299 (CRL-5803, ATCC)
were kept in DMEM low Glucose (Invitrogen, Karlsruhe
Germany), 10% FCS, 2 mM Glutamine. Esophageal
adenocarcinoma cells OE33 (ACC 706, DSMZ) were
maintained in DMEM 1:1 mixture of low and high Glu-
cose, 10% FCS, 2 mM Glutamine. MCF-10A (CRL-
10317, ATCC) cells were grown in DMEM/F12 (1:1),
PAN-Biotech, P04–41250 (L-Glutamine (2,5 mM); HEPE
S (15 mM), NaHCO3 (1,2 g/L), Na-Pyruvat (1 mM)) sup-
plemented with 10% FCS, hEGF (20 ng/ml) Hydrocorti-
son (0,5 μg/ml) Insulin (10 μg/ml) and cholera toxin
(100 ng/mL). HCT116 wild-type cells and the isogenic
double knockout subline HCT116-Bax−/−/Bak−/− were
kindly provided by Dr. R. J. Youle, NIH (Bethesda, MD)
[9]. All cells were grown in DMEM supplemented with
10% FCS, 100,000 units/liter penicillin, and 0.1 g/liter
streptomycin at 37 °C with 5% CO2 in a humidified at-
mosphere. Media and culture reagents were from Invi-
trogen unless stated otherwise. Upon reaching
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approximately 85% confluence, cells were detached with
Accutase (Sigma-Aldrich, Germany) in PBS containing
0.5 mM EDTA, sub cultured in new flasks and used for
the assays.
Cell treatment procedures
Cancer cells were seeded into 6-well plates (2 × 105
cells/2 ml). The next day, in some of the experiments,
cells were treated with Alectinib for 24 h at 37 °C in a
cell incubator. Then, cells were treated with ALA for 3 h
and, depending on the experimental setting, with 10 μM
of the pan caspase inhibitor Q-VD-OPh. After washing,
cells were exposed to a LED emitting light at a wave-
length of 405 nm. Subsequently, cells were kept for 18 h
at 37 °C in a cell incubator. Apoptosis was determined
using an Annexin V-FITC detection kit (BD Biosciences)
according to the manufacturer’s instructions. For flow
cytometric analysis, at least 10,000 cells were evaluated
using a FACSCalibur or LSRFORTESSA (BD Biosci-
ences). Cell cycle distribution and sub-G1 fraction were
determined in a quantitative way using the CellQUEST™
program. Annexin V positive-PI negative cells are
counted as early apoptotic cells. All experiments were
done at least in triplicates.
Immunoblotting
After trypsination, cells were washed twice with ice-cold
PBS and lysed in 10mM Tris-HCl pH 7.5, 137 mM
NaCl, 1% Triton X-100, 2 mM EDTA, 1mM pepstatin,
1 mM leupeptin, and 100 μM phenylmethyl sulfonyl-
fluoride (PMSF). Protein concentration was determined
using the Thermo Scientific Pierce BCA Protein Assay
Kit (Life Technologies GmbH) and equal amounts of
protein (20 μg per lane) were separated by SDS-PAGE.
After electrophoresis proteins were transferred onto
0.2 μm nitrocellulose membranes by semi-dry blotting
using a BioRad Trans-blot SD transfer cell. Membranes
were blocked in blocking buffer (5% BSA, 0.1% Tween-
20 in PBS) for 1 h, followed by an overnight incubation
with primary antibodies in blocking buffer at 4 °C. Pri-
mary antibodies used were anti-Bak mAb (clone TC102)
from Calbiochem (Merck KGaA, Darmstadt, Germany),
anti-Bax mAb (clone YTH-2D2) from Trevigen (Gai-
thersburg, USA) and mouse anti-FECH (A-3) from Santa
Cruz Biotechnology (Heidelberg, Germany). Secondary
antibodies coupled to horseradish peroxidase (from Pro-
mega, Mannheim, Germany) and Pierce ECL Western
Blotting Substrate reagents were used to detect proteins
by chemoluminescence.
Microscopy
Cancer cells were seeded into 6-well plates (2 × 105
cells/2 ml), treated for 24 h with 10 μM Crizotinib or
Alectinib. Thereafter, cells were incubated with 100 μM
ALA for 4 h. Microscopy images were then taken using
an Axiovert 200 inverse fluorescence microscope (Carl
Zeiss, Inc.) equipped with a Hamamatsu ORCA-ER
digital camera using the Openlab software (Improvision).
Mean fluorescence intensity of images was analyzed
using ImageJ 1.53a software (https://imagej.nih.gov/ij/).
Statistical analysis
Experimental data were presented as the mean ± stand-
ard deviation (SD). Statistical analyses were performed
using the GraphPad Prism 5. Student t-test was used for
data analysis between two groups. P-values of less than
0.05 were considered statistically significant.
Results
I. Alectinib induces PpIX-Fluorescence in tumor
cells
Recent studies showed that a novel anti-cancer drug,
Alectinib, is able to bind the FECH-enzyme. Thus, we
suspected that Alectinib inhibits the activity of FECH
within the heme metabolism. In an initial experiment,
we examined how the treatment of cancer cells with
Alectinib affects the generation of PpIX by fluorescence
microscopy detection. As a control treatment here, we
examined Crizotinib which is another multiple tyrosine
kinase inhibitor (TKI) of ALK and has also been ap-
proved for ALK-rearranged NSCLC [8]. Thus, the effects
of both TKIs on generation of PpIX-fluorescence in hu-
man breast cancer cell line MDA-MB-231 were assessed.
Since both TKIs have been approved for treatment of
NSCL also their effects on PpIX accumulation in the
ALK positive NSCLC tumor cell lines H1299 and H460
[10] were examined. Briefly, cells were seeded into 6-
well plates (2 × 105 cells/2 ml RPMI with 10% FCS, 1%
Glutamine). Next day, cells were treated for 24 h at
37 °C in a cell incubator with 10 μM Alectinib or Crizo-
tinib. Upon Alectinib or Crizotinib treatment, cells were
incubated with 100 μM ALA/RPMI medium without
phenol red for 3 h. Then, cells were transferred into an
Axiovert 200M Inverted Fluorescence Microscope
equipped with a 545/30 nm (excitation), 620/60 nm
(emission) filter set, and bright field microscopy pictures
and PpIX-Fluorescence images were obtained by Open-
Lab software (Improvision). Treatment with 10 μM Alec-
tinib induced PpIX-fluorescence in the two NSCLC cell
lines as well as in MDA-MB-231 breast cancer cells,
while Crizotinib was not effective (Fig. 1, mean
fluorescence-intensity of three experiments are shown in
supplemental Fig. 1). Similarly, control treatment with
1% DMSO in PBS was not effective. Thus, we were able
to demonstrate that Alectinib in fact induces an accu-
mulation of PpIX as detected by its specific fluorescence.
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These results are in accordance with data showing that
only Alectinib binds to the FECH protein and not Crizo-
tinib [5, 6]. Interestingly, Alectinib only acted upon
assisting PpIX accumulation in the ALK positive NSCLC
tumor cell lines H1299 and H460, however Crizotinib
did not (Fig. 1).
II. Addition of aminolevulinic acid for induction of
PpIX-Fluorescence in tumor cells
The results of the initial experiment (I) encouraged us
to study the effects of Alectinib in detail. On the one
hand, generation of PpIX can be increased by down-
regulation of the activity of FECH, on the other hand,
generation of PpIX depends on a sufficient intracellular
delivery of the precursor substance (5-ALA). Therefore,
it was necessary to assess the effect of Alectinib on
PpIX-fluorescence with regard to a treatment of cells
with various concentrations of 5-ALA. To this end, the
human breast cancer cell line MDA-MB-231 was incu-
bated with 10 μM Alectinib in 1% DMSO for 24 h at
37 °C in a cell incubator. Since the generation of PpIX
depends also on a sufficient intracellular concentration
of the precursor 5-ALA, cells were pretreated with vari-
ous concentrations of 5-ALA for 3 h. After another
washing step, PpIX-fluorescence of the cells was directly
assessed by flow cytometry with an excitation of 405 nm
and emission at 698 nm (Filter 695/40). Treatment with
Alectinib dissolved in DMSO resulted in a higher PpIX-
fluorescence compared to treatment with DMSO alone
for concentrations of 5-ALA up to 250 μM. In any case,
there is a significant difference between treatment with
Alectinib and control (p < 0.001, t-test), except at a 5-
ALA-concentration of 500 μM. The highest significant
difference between Alectinib and control was found at
an ALA-concentration of 150 μM (Fig. 2). ALA exceeds
the effect of Alectinib on PpIX-fluorescence at higher
concentrations. For further experiments we chose a 5-
ALA concentration of 150 μM.
III. Induction of PpIX-fluorescence and cell apop-
tosis by treatment with light.
After treatment with light, PpIX is able to transfer that
energy to molecular oxygen, leading to generation of re-
active oxygen species (ROS) responsible for cellular oxi-
dation and subsequent apoptosis or necrosis of tumor
cells [1]. Here, we were interested to see how a specific
light treatment induced apoptosis in MDA-MB-231
breast cancer cells. To this end, exposure of cells to LED
light of 405 nm was assessed. Cells were pretreated with
250 μM 5-ALA for 3 h. After washing, cells were ex-
posed to a LED emitting light at a wavelength of 405
nm, which was operated at 25 mA leading to an intensity
of 4 mW/cm2. Duration of light treatment was between
20min and 180 min within the cell incubator. After light
treatment, apoptosis was determined by flow cytometric
analysis of cells, stained for phosphatidylserine exposure
by use of an Annexin V-FITC detection kit (BD Biosci-
ences). Exposure of 5-ALA pretreated MDA-MB-231
breast cancer cells to LED light led to a rate of about
20% apoptotic, Annexin V-FITC positive cells (Fig. 3). A
treatment of 60 min turned out to be sufficient for this
apoptosis rate. There were no significant differences be-
tween any of the exposure times. Recently, it has shown
that the triple-negative breast cancer cells MDA-MB-
Fig. 1 Fluorescence of NSCLC and breast cancer cells after treatment with Alectinib. NSCLC cells H460, H1299 and MDA-MB-231 breast cancer
cells were treated for 24 h with 10 μM Crizotinib (middle rows) or Alectinib (lower rows) in 6 well plates. Thereafter, cells were incubated with
100 μM ALA for 4 h. Bright field microscopy pictures (left columns) and PpIX-Fluorescence (right columns) were assessed in parallel using Axiovert
200 M Inverted Fluorescence Microscope. Treatment with Alectinib induced PpIX-fluorescence in the cancer cells, while Crizotinib was not
effective. (Magnification bar = 25 μm)
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231 display a high susceptibility to PDT [11]. Since we
want to compare the MDA-MB-231 cells with other cell
lines which might be less susceptible an exposure time
of 60 min was chosen for further experiments.
IV. Induction of phosphatidylserine exposure by
Alectinib and light treatment
Now we asked how light treatment affects cell death
induction by Alectinib. The breast cancer cell line
MDA-MB-231 but also human NSCLC cancer cell
lines NCI-H460 and NCI-H1299 were treated with
10 μM Alectinib as above (II). After washing, cells
were treated with 150 μM 5-ALA for 3 h. After an-
other washing step, cells were exposed to a LED
emitting light as above (III) and apoptosis was deter-
mined by flow cytometric analysis of Annexin V-FITC
stained cells. ALA-treatment did not significantly
change induction of apoptosis. In contrast, additional
Alectinib treatment induced phosphatidylserine expos-
ure in all three human cancer cell lines, around 26%
of the NCI-H460, 18% of NCI-H1299 and 26% of the
MDA-MB-231 cells were positive for Annexin V-
FITC staining (Fig. 4). Upon light exposure, however,
cells showing a positive staining for Annexin V-FITC
increased up to 42, 30 and 35%, respectively (Fig. 4,
columns on the right side). In order to analyze
whether treatment with Alectinib could be deleterious
for the normal peripheral tissue in addition we
assessed cell death induction by Ale/ALA/Light treat-
ment in the non-tumorigenic human breast cell line
MCF-10A. As shown for the other tumor cell lines,
Alectinib induced cell death also in MCF-10A cells.
Fig. 2 Addition of ALA increased Alectinib-stimulated PpIX-fluorescence breast cancer cells. Human breast cancer cell lines MDA-MB-231
were incubated with 10 μM Alectinib for 24 h. Subsequently, cells were treated with ALA (X-axis) for 3 h. PpIX-fluorescence (Y-axis, arbitrary units)
of the cells was directly assessed by flow cytometry with an excitation of 405 nm and emission at 698 nm (Filter 695/40). Treatment with Alectinib
(dashed line) dissolved in DMSO resulted in a higher PpIX-fluorescence compared to treatment with DMSO alone (solid line) for concentrations of
ALA up to 250 μM. Depicted is the median of three measurements
Fig. 3 Induction of phosphatidylserine exposure in breast
cancer cells due to LED light treatment. Light induction of
apoptosis in MDA-MB-231 breast cancer cells pretreated with
250 μM ALA. LED lamp emitting light at a wavelength of 405 nm
was operated at 25 mA leading to an intensity of 4 mW/cm2.
Duration of light treatment was between 20 min. and 180min. (X-
axis). Apoptosis was determined using an Annexin V-FITC detection
kit by flow cytometry. Exposure of ALA-pretreated MDA-MB-231
breast cancer cells to LED light led to a rate of about 20% apoptotic
cells. (Data show mean ± SD of three independent experiments;
* p < 0.05)
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However, the rate of cell death is not increased by
additional LED light irradiation in MCF-10A cells
(Fig. 4). In contrast, exposure of the cancer cell lines
to LED light (405 nm) increased the effect of Alecti-
nib significantly (p < 0.05) for all cell lines. Therefore,
this combination of Alectinib treatment and exposure
to a LED emitting light at a wavelength of 405 nm
was used in further experiments.
V. Induction of apoptosis by Alectinib in various
cancer cell lines
Cells of various cancer cell lines such as the breast car-
cinoma line MDA-MB-231, esophageal adenocarcinoma
OE33, gastric carcinoma MKN28, colorectal carcinoma
SW480, and NSCLCs NCI-H460 and NCI-H1299 were
treated as above (10 μM Alectinib, 150 μM 5-ALA for 3
h, and LED emitting light at a wavelength of 405 nm for
one hour). Apoptosis was determined by flow cytometric
analysis of Annexin V-FITC stained cells. In addition,
cells were counterstained with propidium iodide (PI) to
distinguish early apoptotic cells (Annexin V-positive/PI-
negative) and late apoptotic/necrotic cells. Combined
Fig. 4 Light treatment increased Alectinib-induced phosphatidylserine exposure of NSCLC and breast cancer cells. NSCLC cells H460,
H1299 and MDA-MB-231 breast cancer cells were / or were not treated with 10 μM Alectinib, 150 μM ALA, and exposure to a LED lamp emitting
light at a wavelength of 405 nm (X-axis). Phosphatidylserine exposure (Y-axis) was determined using an Annexin V-FITC detection kit by flow
cytometry. Light treatment (black columns) increased the effect of Alectinib (right side of each figure) significantly. In H460, H1299 and MDA-MB-
231 cell lines light treatment (black columns) increased the effect of Alectinib (right side of each figure) significantly (* p < 0.05). In contrast, in the
non-tumorigenic human breast cell line MCF-10A the rate of cell death is not increased by additional LED light irradiation. (mean ± SD of three
independent experiments; * p < 0.05)
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treatment of cells with Alectinib and LED light led to
enhanced cell death in all cells (Figs. 5 and 7). However,
the proportion of early apoptotic cells and late apop-
totic/necrotic cells varied between the different cell lines.
Treatment with Alectinib and LED Light exposure en-
hances cell death in the cancer cell lines MDA-MB-231,
MKN-28 and OE33 also without addition of ALA. In all
four cell lines (including SW-480) cell death induced by
LED Light is further stimulated by pre-treatment of cells
with 5-ALA (Fig. 7). We next examined the status of
FECH of all cell lines upon treatment with Alectinib by
Western blotting using an antibody specific for FECH
and the ImageLab software 6 (Bio-Rad) for quantifica-
tion of the relative expression (Fig. 5, right). As expected
all cell lines strongly express FECH and Alectinib treat-
ment did not lead to a change in FECH expression, with
the exception of SW480 cells where FECH expression
was slightly reduced. Interestingly, FECH expression did
not correlate with the sensitivity of the cells for cell
death induction, indicating that kinetics of cell death in-
duction by apoptotic or necrotic signaling pathways dif-
fer between cell lines. In addition to FECH we therefore
examined expression of key pro- and anti-apoptotic Bcl-
2 family members. All cell lines strongly express Bak
and Bax, with the strongest Bax expression seen in
MKN28 and SW480 cells (Supplemental Fig. 3). In com-
parison, the expression of the anti-apoptotic Bcl-2 and
Bcl-xL, important inhibitors of Bax and Bak, respectively,
varies more between cell lines. Bcl-2 expression is barely
detectable in OE33, MKN28 and SW480 cells, likewise
Bcl-xL expression in H460 and H1299 cells. In most cell
lines, the BH3-only protein Puma is barely detectable or
only weakly expressed, with the exception of MKN28
with relatively strong Puma expression. The effect of
Alectinib on the expression of Bcl-xL, Bcl-2 Bax, and
Bak appears to be rather small overall. However, Puma
expression is increased after Alectinib treatment in
MDA-MB-231 and OE33 cells, but decreased in MKN28
and HCT116 cells (Supplemental Fig. 3).
VI. Induction of apoptosis by Alectinib in a Bax/
Bak double knockout line
The next question was whether cell death is induced
by the intrinsic mitochondrial Bax/Bak dependent path-
way or if other cell death signaling pathways are in-
volved in cell death induction by the combined
treatment. Therefore, HCT116 wild-type (wt) cells and
the isogenic double knockout subline HCT116-Bax−/−/
Bak−/− cells were treated as above (10 μM Alectinib,
150 μM 5-ALA for 3 h, and LED emitting light at a
wavelength of 405 nm for one hour). Knockout of Bax
and Bak was confirmed by WB analysis, showing loss of
expression in HCT116-Bax−/−/ Bak−/− cells (Fig. 6, right).
Fig. 5 Apoptosis induction by Alectinib and light treatment in carcinoma cell lines. A) Cells of various cancer cell lines such as the breast
carcinoma line MDA-MB-231, esophageal adenocarcinoma OE33, gastric carcinoma MKN28, colorectal carcinoma SW480 and NSCLC cells H460,
H1299 were treated with DMSO alone or with 10 μM Alectinib/DMSO, 150 μM ALA, and LED light. Cells were stained using an Annexin V-FITC
detection kit, counterstained by PI and apoptotic cells were determined by flow cytometry. Annexin V-positive/PI-negative cells were considered
as early apoptotic cells, Annexin V-positive/PI-positive cells were late apoptotic/necrotic cells. Combined treatment of cells with Alectinib, ALA
and LED light led to enhanced cell death in all the cell lines. (mean ± SD of three independent experiments; * p < 0.05) B) Densitometric analysis
of Western Blot reveals that all cell lines strongly express FECH and that FECH expression levels were not changed by Alectinib treatment, except
for SW480 cells where expression is slightly reduced. Level of FECH expression was normalized to respective actin control and presented as
relative protein expression level in relation to respective wild type control. (Analysis was performed twice. Both WB including quantification and
indication of the mean value are shown in the supplemental Fig. 2)
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Cells were stained with Annexin V-FITC/PI and ana-
lyzed by FACS. Combined treatment of cells with Alecti-
nib, 5-ALA and light led to enhanced cell death in
HCT116 wt cells. Especially the number of Annexin V-
positive/PI-negative (early apoptotic) cells is strongly in-
creased (Fig. 6), indicating induction of apoptosis upon
treatment. Compared to wt cells the number of early
apoptotic cells is strongly decreased in Bax/Bak deficient
HCT116 cells. However, although Bax/Bak deficiency
blocks induction of early apoptosis, the number of
Annexin V-positive/PI-positive (late apoptotic/necrotic)
cells increased from around 11% in the wt cell line to
19% in the HCT 116-Bax−/−/Bak−/− cell line upon treat-
ment (Fig. 6, right). Interestingly, the number of
Annexin V-positive/PI- positive (late apoptotic/necrotic)
cells shows a significant increase in HCT116
Bax−/−Bak−/− upon treatment compared to untreated
HCT116 Bax−/−Bak−/− cells (Fig. 6, right columns). The
differential sensitivity of wt and Bax/Bak deficient cells is
not due to altered FECH expression as WB analysis re-
veals similar expression of FECH in both cell sublines
(Fig. 6, right) demonstrating that sensitivity of cancer
cells for cell death induction by Alectinib/light treatment
essentially depends on the activity of various cell death
signaling pathways.
In addition to the role of Bax and Bak we also ana-
lyzed whether caspases are involved in cell death induc-
tion upon combined Ale/ALA/Light treatment.
Therefore, caspase activity was blocked by incubation of
the tumor cell lines with the pan-caspase inhibitor Q-
VD-OPh prior to the combined Ale/ALA/Light treat-
ment. Flow cytometric analysis revealed that
Fig. 6 Apoptosis Induction by Alectinib and light treatment in HCT116 Bax−/− / Bak−/−. HCT116 wild-type (WT) cells and isogenic double
knockout subline HCT116-Bax−/−/Bak−/− cells were treated with DMSO alone or 10 μM Alectinib/DMSO, 150 μM, and LED light. Combined
treatment of cells with Alectinib and light induced cell death in both cell lines, but number of Annexin V-positive/PI-negative was significantly
reduced and number of Annexin V-positive/PI-positive increased in the double knockout cells in comparison to HCT116 WT (Data show mean ±
SD of three independent experiments; * p < 0.05). WB analysis (right side) confirmed loss of Bax and Bak expression in HCT116 double knock out
cells and shows that FECH expression in HCT116-wt cells and isogenic HCT116-Bax−/−/Bak−/− cells is comparable. Level of FECH expression was
normalized to respective actin control and presented as relative protein expression level in relation to respective wild type control. (Analysis was
performed twice. Both WB including quantification and indication of the mean value are shown in the supplemental Fig. 2)
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pretreatment of cells with the pan-caspase inhibitor Q-
VD-OPh potently reduced the proportion of apoptotic
cells in all cell lines tested (Fig. 7, right) indicating in-
duction of apoptotic cell death upon combined treat-
ment. Interestingly, neither Bax/Bak deficiency nor
caspase inhibition completely inhibited cell death induc-
tion by the combined treatment, indicating that in
addition to apoptosis alternative pathways are involved
in the induction of cell death upon Ale/ALA/Light
treatment.
Discussion
A highly selective treatment for malignant cells is photo-
dynamic treatment with 5-ALA. Beneficial effects of
ALA-PDT have been demonstrated for various carcin-
omas, e.g. [12]. Recently, Hatakeyama et al. [13] showed
that ALA-PDT using LED light is effective and useful for
the treatment of colorectal carcinomas. Here, we were
able to demonstrate that the efficiency of ALA-PDT
could be enhanced by treatment of cancer cells with
Alectinib, an orally available, highly selective, potent
second-generation inhibitor of anaplastic lymphoma tyr-
osinkinase (ALK). Cancer cell lines of different origin
such as the breast carcinoma line MDA-MB-231,
esophageal adenocarcinoma OE33, gastric carcinoma
MKN28, colorectal carcinoma SW480, and NSCLCs
NCI-H460 and NCI-H1299 were examined. Combined
treatment of cells with Alectinib and LED light led to
Fig. 7 Apoptosis Induction by Alectinib and light treatment upon caspase inhibition. LED Light exposure enhances Alectinib-induced cell
death in the cancer cell lines MDA-MB-231, MKN-28 and OE33 also in the absence of ALA. In all four cell lines (including SW-480) cell death
induced by PDT after Alectinib treatment is further stimulated by 5-ALA. In order to investigate the role of caspases for Alectinib/PDT on a
functional level, caspase activity was blocked by incubation of the cells with 10 μM of the cell-permeable, broad-spectrum caspase inhibitor Q-VD-
Oph 2 h prior Alectinib/ALA/Light treatment. FACS analysis of treated cells revealed that caspase inhibition potently reduced the proportion of
apoptotic cells in all cell lines. (Data show mean ± SD of three independent experiments; * p < 0.05)
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enhanced cell death in each cell line (Fig. 5). Interest-
ingly, since Alectinib promotes PpIX accumulation also
in the ALK positive NSCLC tumor cell lines H1299 and
H460, an additive treatment of NSCLC with ALA-PDT
might enhance the beneficial therapeutic effect of Alecti-
nib in these carcinomas. In contrast to the tumor cell
lines, the rate of cell death is not increased by PDT with
Alectinib treatment in non-tumorigenic human MCF-
10A breast cells (Fig. 4). In agreement with the low sen-
sitivity of non-tumorigenic MCF-10A cells to PDT with
Alectinib shown here, a recent study has shown that
non-tumorigenic human breast cells also are more re-
sistant to PDT using methylene blue as photosensitizer
(MB-PDT), whereas very aggressive triple-negative
breast cancer cells (TNBCs) displayed high susceptibility
to MB-PDT induced cell death [11]. Upon photooxida-
tion MB disrupts lysosome integrity and induces lyso-
somal membrane permeabilization (LMP), which is
accompanied by necroptosis or both necroptosis and fer-
roptosis in non-invasive and highly aggressive tumor
cells, respectively. However, in non-tumorigenic human
breast cell MB-PDT is accompanied by an antioxidant
response and the enhanced ability of non-tumorigenic
cells to deal with photo-oxidative damage confers
resistance.
Another focus of our interest was to investigate whether
cell death is induced by the intrinsic mitochondrial Bax/
Bak dependent pathway or if other cell death signaling
pathways are involved in cell death induction by the com-
bined treatment. Inhibition of the intrinsic apoptosis path-
way by Bax/Bak deletion only partially inhibits cell death
induced by Ale/ALA/Light treatment. Likewise, inhibition
of caspases by the pan-caspase inhibitor Q-VD-OPh only
provides partial protection against the treatment, indicat-
ing that alternative caspase-independent mechanisms are
involved in the induction of cell death. In line with these
results, it has been shown, that PDT can kill cancer cells
by the efficient induction of apoptotic as well as of non-
apoptotic cell death pathways including necrosis and
necroptosis, depending on the photosensitizer, PDT
protocol, and tumor type [14–17]. These different forms
of cell death are not mutually exclusive. Furthermore, in-
duction of autophagy in photosensitized cells is a common
phenomenon of PDT [18]. In apoptosis-deficient murine
embryonic fibroblasts lacking Bax and Bak PDT stimulates
a form of caspase-independent cell death, with a necrotic
morphotype, for which aberrant autophagy stimulation is
required [19]. However, the role of autophagy as a factor
in PDT-induced cell death is not yet clear, as autophagy
can also serve as a protective mechanism [17, 20]. An in-
teresting paper published recently by Dos Santos et al.
[11] showed that in breast cancer cells lysosomal mem-
brane permeabilization is a common event upon PDT
which is accompanied by an antioxidant response in non-
tumorigenic cells, necroptosis in non-invasive tumor cells,
and both necroptosis and ferroptosis in highly aggressive
triple-negative tumor cells.
As mentioned above, Alectinib demonstrates a favorable
safety profile and clinically meaningful response in pa-
tients with ALK-positive metastatic NSCLC [8] and was
granted accelerated approval by the FDA. Our data sug-
gest that an additive treatment of NSCLC with ALA-PDT
might even enhance the beneficial therapeutic effect of
Alectinib in these carcinomas. On the other hand, Alecti-
nib has some side effects such as hepatic toxicity (see e.g.
Rxlist, https://www.rxlist.com). This has to be checked
very carefully in the clinical setting. In the future there
might be alternative PDT-treatments with less side effects,
however still the majority of current on-going trials are
using photosensitizers that have already approved for clin-
ical use, such as ALA [21]. As described here, the results
of ALA-PDT could be improved by Alectinib. In the case
of patients suffering from metastasized gastrointestinal
carcinomas there are only very few treatment options.
Therefore, in these cases the risk of side effects of ALA-
Alectinib-PDT can be accepted.
Peritoneal dissemination represents a devastating form
of colorectal, gastric, pancreatic or ovarian cancer progres-
sion with a dismal prognosis. Colorectal cancer is the third
common cancer, of which the peritoneum is the second
most common metastatic site [22] [23]. Peritoneal dissem-
ination is identified in nearly 10% of colorectal cancer pa-
tients when initially diagnosed, and in 20–50% of patients
with recurrent disease [22]. For gastric cancer, the 5-year
survival rate of patients with peritoneal dissemination is
only 2% [24]. Diagnosing minimal peritoneal dissemin-
ation improves the prognosis because the patients
undergo chemotherapy treatment earlier. Kondo et al.
[25] observed better diagnostic accuracy using 5-ALA
photodynamic diagnosis compared to conventional lapar-
oscopy in patients with colorectal cancer. According to
their investigations, 5-ALA photodynamic diagnosis is a
promising candidate for diagnosing peritoneal dissemin-
ation in colorectal cancer. Recent papers discusses the
perspectives of photodynamic diagnosis for peritoneal dis-
semination [26] [27].
Conclusions
Photodynamic treatment of tumor cell lines of different
origin in combination with Alectinib increased
protoporphyrin-IX specific fluorescence and concomi-
tantly cell death. Thus, the usage of Alectinib could be
another step for enhancing the effectiveness of photo-
dynamic therapy. Since Alectinib promotes PpIX accu-
mulation also in the ALK positive NSCLC tumor cell
lines H1299 and H460, an additive treatment of NSCLC
with ALA-PDT might enhance the beneficial therapeutic
effect of Alectinib in these carcinomas. Moreover,
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further experiments in animal models with peritoneal
metastases of gastrointestinal carcinomas will show
whether a combination of an ALA based photodynamic
therapy with Alectinib treatment could be a new strategy
for diagnosis or even treatment of peritoneal dissemi-
nated carcinomas.
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Additional file 1: Supplemental Fig. 1. Increased fluorescence-
intensity upon Alectinib treatment. Mean fluorescence-intensity of NSCLC
cells H460, H1299 and MDA-MB-231 breast cancer cells was increased
upon Alectinib treatment while Crizotinib was not effective. Cells were
treated as described in Fig. 1. Fluorescence images were assessed using
Axiovert 200 M Inverted Fluorescence Microscope and mean
fluorescence-intensity analyzed by Image 1.53a software. (mean ± stand-
ard deviation of three experiments; * p < 0.05).
Additional file 2: Supplemental Fig. 2. Quantification of FECH
expression. FECH Western Blots were quantified by use of the ImageLab
software 6 (Bio-Rad). Level of FECH expression, was normalized to the
respective actin control and presented as the relative expression level in
relation to respective wild type control. Analysis of FECH expression by
WB analysis was performed twice in independent experiments. The
upper blots are identical to the respective blots from Figs. 5 and 6.
Additional file 3: Supplemental Fig. 3. Expression levels of key pro-
and anti-apoptotic Bcl-2 family members. Cell lines strongly express Bak
and Bax, with the strongest Bax expression seen in MKN28 and SW480
cells. Expression of anti-apoptotic Bcl-2 and Bcl-xL, varies between cell
lines. Puma is barely detectable or only weakly expressed, with the excep-
tion of MKN28 with relatively strong Puma expression. The effect of Alec-
tinib on expression appears to be rather small overall. However, Puma
expression is increased after Alectinib treatment in MDA-MB-231 and
OE33 cells, but decreased in MKN28 and HCT116 cells (quantified by Ima-
geLab software 6 (Bio-Rad), − not calculated due to low expression).
Additional file 4: Supplemental Fig. 4. Intensity of LED light source.
Measured intensity (power per area) vs. supply current for the 405 nm
LED lamp. Parameter is the distance between lamp and illuminated area.
If the is lamp operated at 25 mA and the distance between LED and
sample is 25 mm, intensity is 4 mW/cm2.
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